cdri 85-287 has been researched along with afimoxifene in 1 studies
| Studies (cdri 85-287) | Trials (cdri 85-287) | Recent Studies (post-2010) (cdri 85-287) | Studies (afimoxifene) | Trials (afimoxifene) | Recent Studies (post-2010) (afimoxifene) |
|---|---|---|---|---|---|
| 22 | 0 | 3 | 1,255 | 10 | 325 |
| Protein | Taxonomy | cdri 85-287 (IC50) | afimoxifene (IC50) |
|---|---|---|---|
| Phospholipase D2 | Homo sapiens (human) | 6.5 | |
| Estrogen receptor | Homo sapiens (human) | 0.0105 | |
| Estrogen-related receptor gamma | Homo sapiens (human) | 0.0084 | |
| Phospholipase D1 | Homo sapiens (human) | 6.5 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.0102 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dalela, D; Gupta, G; Jain, A; Jain, RK; Kumar, R; Maikhuri, JP; Sarswat, A; Sharma, VL; Verma, V | 1 |
1 other study(ies) available for cdri 85-287 and afimoxifene
| Article | Year |
|---|---|
Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
Topics: 5-alpha Reductase Inhibitors; Animals; Apoptosis; Aromatase; Benzopyrans; Cell Proliferation; Cell Survival; Cells, Cultured; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Finasteride; Gene Expression Regulation; Humans; Male; Piperidines; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Receptors, Androgen; RNA, Messenger; Selective Estrogen Receptor Modulators; Signal Transduction; Stromal Cells; Tamoxifen; Testosterone; Tissue Culture Techniques | 2012 |